Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment

World Journal of Surgical Oncology

Gang Cao¹  Xianglong Duan¹  Xin Xu¹  Jie Li¹  Zhiliang Wang¹ 

[1] Department of General Surgery, The Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an 710004, China

关键词: Urea;    Targeted therapy;    Immunoliposome;    Hemangioma;    HVECs;    Anti-VEGFR;   

Others  :  820807
DOI  :  10.1186/1477-7819-11-300

 received in 2013-06-04, accepted in 2013-11-17,  发布年份 2013

【 摘 要 】

Background

Urea injection has been used in hemangioma treatment as sclerotherapy. It shrinks vascular endothelial cells and induces degeneration, necrosis, and fibrosis. However, this treatment still has disadvantages, such as lacking targeting and difficulty in controlling the urea dosage. Thus, we designed a urea immunoliposome to improve the efficiency of treatment.

Methods

The urea liposome was prepared by reverse phase evaporation. Furthermore, the urea immunoliposome was generated by coupling the urea liposome with a vascular endothelial growth factor receptor (VEGFR) monoclonal antibody using the glutaraldehyde cross-linking method. The influence of the urea immunoliposome on cultured human hemangioma vascular endothelial cells was observed preliminarily.

Results

Urea immunoliposomes showed typical liposome morphology under a transmission electron microscope, with an encapsulation percentage of 54.4% and a coupling rate of 36.84% for anti-VEGFR. Treatment with the urea immunoliposome significantly inhibited the proliferation of hemangioma vascular endothelial cells (HVECs) in a time- and dose-dependent manner.

Conclusions

The urea immunoliposome that we developed distinctly and persistently inhibited the proliferation of HVECs and is expected to be used in clinical hemangioma treatment.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Miller T, Frieden IJ: Hemangiomas: new insights and classification. Pediatr Ann 2005, 34:179-187.
• [2]Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA: Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93:2357-2364.
• [3]Li GC, Gu JZ: Infantile Hemangioma. 1st edition. Xian: Shaanxi Science and Technology Press; 1991.
• [4]Wang XZ, Li GC, Gu JZ: Seclective arterial catheterization and urea injection treatment of huge cavernous hemangiomas. Zhonghua Wai Ke Za Zhi 1985, 23:367-368.
• [5]Qiao JB, Li J, Ma YC, Guo XN, Zhu XS, Dong CX: Combined treatment with urea injection and surgical procedure for the scrotal vein malformation in teenagers. Zhonghua Zheng Xing Wai Ke Za Zhi 2012, 28:256-260.
• [6]Walter JW, North PE, Waner M, Mizeracki A, Biei F, Walker JW, Reinisch JF, Marchuk DA: Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chrom Cancer 2002, 33:295-303.
• [7]Ritter MR, Dorrell MI, Edmonds J: Insulin-like growth factor-2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002, 99:7455-7460.
• [8]Berard M, Sordel S, Ortega N: Vascular edothelial growth advantage in vitro and in vivo stromal cells cultured from neonatal hemangiomas. Am J Path 1997, 150:1315-1326.
• [9]Shama G, Anabousi S, Ehrhardt C, Ravi Kumar MN: Liposomes as targeted drug delivery systems in the treatment of breast cancer. J Drug Target 2006, 14:301-310.
• [10]Stuart DD, Semple SC, Allen TM: High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol 2004, 387:171-188.
• [11]Law SL, Huang KJ, Chiang CH: Acyclovir-containing liposomes for potential ocular delivery, corneal penetration and absorption. J Control Release 2000, 63:135-140.
• [12]Were LM, Bruce BD, Davidson PM, Weiss J: Size, stability, and entrapment efficiency of phospholipid nanocapsules containing polypeptide antimicrobials. J Agric Food Chem 2003, 51:8073-8079.
• [13]Frkanec R, Travas D, Krstanović M, Spoliar BH, Lievaković D, Vranesić B, Frkane L, Tomasić J: Entrapment of peptidoglycans and adamantyltripeptides into liposomes: an HPLC assay for determination of encapsulation efficiency. J Liposome Res 2003, 13:279-294.
• [14]Uihlein LC, Liang MG, Mulliken JB: Pathogenesis of infantile hemangiomas. Pediatr Ann 2012, 41:1-6.
• [15]Park JW, Benz CC, Martin FJ: Future direction of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004, 31:196-205.